The TROV chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the TROV chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The TROV stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View TROV Detailed Price Forecast - CNN Money||View TROV Detailed Summary - Google Finance|
|View TROV Detailed Summary - Yahoo! Finance||View TROV Stock Research & Analysis - Zacks.com|
|View TROV Trends & Analysis - Trade-Ideas||View TROV Major Holders - Barrons|
|View TROV Call Transcripts - NASDAQ||View TROV Breaking News & Analysis - Seeking Alpha|
|View TROV Annual Report - CompanySpotlight.com||View TROV OTC Short Report - OTCShortReport.com|
|View TROV Fundamentals - TradeKing||View TROV SEC Filings - Bar Chart|
|View Historical Prices for TROV - The WSJ||View Performance/Total Return for TROV - Morningstar|
|View the Analyst Estimates for TROV - MarketWatch||View the Earnings History for TROV - CNBC|
|View the TROV Earnings - StockMarketWatch||View TROV Buy or Sell Recommendations - MacroAxis|
|View the TROV Bullish Patterns - American Bulls||View TROV Short Pain Metrics - ShortPainBot.com|
|View TROV Stock Mentions - StockTwits||View TROV Stock Mentions - PennyStockTweets|
|View TROV Stock Mentions - Twitter||View TROV Investment Forum News - Investor Hub|
|View TROV Stock Mentions - Yahoo! Message Board||View TROV Stock Mentions - Seeking Alpha|
|View Insider Transactions for TROV - SECform4.com||View Insider Transactions for TROV - Insider Cow|
|View TROV Major Holdings Summary - CNBC||View Insider Disclosure for TROV - OTC Markets|
|View Insider Transactions for TROV - Yahoo! Finance||View Institutional Holdings for TROV - NASDAQ|
|View TROV Stock Insight & Charts - FinViz.com||View TROV Investment Charts - StockCharts.com|
|View TROV Stock Overview & Charts - BarChart||View TROV User Generated Charts - Trading View|
Methodology to assess changes in leukemic cells, genomic alterations and pTCTP status for Phase 1b /2 Clinical Trial of PCM-075. Update on clinical trial recruitment. SAN DIEGO , April 17, 2018 /PRNewswire/ ...
Combination of PCM-075, a highly-selective Polo-like Kinase 1 (PLK1) inhibitor, and Quizartinib resulted in 97% tumor growth inhibition and regression in FLT3 AML model SAN DIEGO , April 16, 2018 /PRNewswire/ ...
Trovagene Announces Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2018
Posted on Thursday April 12, 2018
SAN DIEGO , April 12, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, developing targeted therapeutics for the treatment of hematologic and solid tumor ...
Trovagene to Present at the 26th Annual Wall Street Investor Conference
Posted on Tuesday March 20, 2018
SAN DIEGO, March 20, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage precision medicine biotechnology company, developing targeted therapeutics to treat hematologic and solid tumor cancers, announced today that it will be presenting at The Wall Street Investor Forum 26th Annual Investor Conference in New York City at The University Club of NYC at 2:05 PM EDT / 11:05 AM PDT on Thursday, March 22, 2018. Bill Welch, Chief Executive Officer of Trovagene, will be presenting, as well as meeting with investors. Trovagene is a precision medicine biotechnology company developing oncology therapeutics for improved cancer care by leveraging its proprietary Precision Cancer Monitoring® (PCM) technology in tumor genomics. Trovagene has broad intellectual property and proprietary technology to measure circulating tumor DNA (ctDNA) in urine and blood to identify and quantify clinically actionable markers for predicting response to cancer therapies. Trovagene offers its PCM technology at its CLIA/CAP – accredited laboratory and plans to continue to vertically integrate its PCM technology with precision cancer therapeutics. For more information, please visit https://www.trovagene.com.